References:
1. Lederer DJ, Martinez FJ: Idiopathic Pulmonary Fibrosis.N Engl J Med 2018, 378: 1811-1823.
2. Podolanczuk AJ, Thomson CC, Remy-Jardin M, Richeldi L, Martinez FJ,
Kolb M, Raghu G: Idiopathic pulmonary fibrosis: state of the art
for 2023. Eur Respir J 2023, 61 .
3. Liu GY, Budinger GRS, Dematte JE: Advances in the management
of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.BMJ 2022, 377: e066354.
4. Richeldi L, Fletcher S, Adamali H, Chaudhuri N, Wiebe S, Wind S, Hohl
K, Baker A, Schlenker-Herceg R, Stowasser S, Maher TM: No
relevant pharmacokinetic drug-drug interaction between nintedanib and
pirfenidone. Eur Respir J 2019, 53 .
5. Ruwanpura SM, Thomas BJ, Bardin PG: Pirfenidone: Molecular
Mechanisms and Potential Clinical Applications in Lung Disease.Am J Respir Cell Mol Biol 2020, 62: 413-422.
6. Takehara K, Koga YA-O, Hachisu YA-O, Utsugi M, Sawada Y, Saito Y,
Yoshimi S, Yatomi M, Shin Y, Wakamatsu I, et al: Differential
Discontinuation Profiles between Pirfenidone and Nintedanib in Patients
with Idiopathic Pulmonary Fibrosis. LID - 10.3390/cells11010143
[doi] LID - 143.
7. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y,
Richeldi L, Kolb M, Tetzlaff K, Stowasser S, et al: Nintedanib
in Progressive Fibrosing Interstitial Lung Diseases. N Engl J
Med 2019, 381: 1718-1727.
8. Crestani B, Huggins JT, Kaye M, Costabel U, Glaspole I, Ogura T, Song
JW, Stansen W, Quaresma M, Stowasser S, Kreuter M: Long-term
safety and tolerability of nintedanib in patients with idiopathic
pulmonary fibrosis: results from the open-label extension study,
INPULSIS-ON. Lancet Respir Med 2019, 7: 60-68.
9. Feagins LA, Abdelsayed GG, Schairer J: Reporting Adverse Drug
Events.
10. Basile AO, Yahi A, Tatonetti NP: Artificial Intelligence for
Drug Toxicity and Safety.
11. Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan
SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U: